Hormone medicines

Buserelin

A GnRH agonist used in specialist hormonal care, with endometriosis research showing pain improvement alongside bone loss.

Small human endometriosis studies plus current UK product information

Also known as: Suprecur

Buserelin molecular structure — Structure reference · C60H86N16O13

Practical use

Evidence interpretation and clinical context

Match the formulation and indication: The injection label reviewed here concerns specialist ovulation-induction preparation.
Keep bone outcomes visible: Hormonal symptom relief can coexist with loss of bone mineral.
Read the actual trial question: Enrollment of infertile women does not make pain relief a fertility outcome.

Buserelin acetate in the treatment of pelvic pain associated with minimal and mild endometriosis: a controlled study.

Hormone treatment related bone mineral content changes in Japanese women with endometriosis.

Current UK product context — primary or official source

Overview

Buserelin activates gonadotropin-releasing hormone receptors. Sustained stimulation can desensitize the pituitary and suppress downstream gonadal hormone production. Its effects therefore differ from a simple testosterone-boosting claim.

Risks and limitations

Bone loss, low-estrogen symptoms and mood effects are material concerns. The current UK product information also addresses severe depression, altered glucose tolerance and QT-related risk in relevant patients. Assisted-reproduction use adds its own procedure-related considerations.

How to read this

An agonist can ultimately suppress a hormonal pathway when prolonged stimulation changes receptor responsiveness. The sequence matters more than the everyday assumption that agonist always means more hormone.

Research explained

Buserelin acetate in the treatment of pelvic pain associated with minimal and mild endometriosis: a controlled study.

Who was studied

35 infertile women with minimal or mild endometriosis randomized to buserelin or expectant management.

What was found

Pain symptoms improved during treatment, and improvement persisted in approximately half of treated participants after withdrawal. Some untreated participants also improved spontaneously.

What it cannot establish

The trial was small and used expectant management rather than a blinded placebo. Pain effects do not establish improved fertility.

Read the original study

Hormone treatment related bone mineral content changes in Japanese women with endometriosis.

Who was studied

19 Japanese women with endometriosis: ten received buserelin and nine danazol over six months.

What was found

Lumbar trabecular bone mineral content fell by about 10% on average in the buserelin group and recovered only partially over the subsequent six months.

What it cannot establish

This was a small study using a particular CT-based bone measurement. Its percentage should not be generalized to every skeletal site or treatment setting.

Read the original study

Current UK product context

The Suprecur injection product information reviewed here lists pituitary desensitization in preparation for ovulation induction. Other research settings and formulations must not be silently substituted for this exact indication.

Supporting source

Benefit and harm use different endpoints

Pain relief and bone loss can both be true. A useful evidence summary retains both rather than treating symptom improvement as a complete benefit-risk judgment.

Supporting source